Literature DB >> 7815562

Papillomavirus capsid binding and uptake by cells from different tissues and species.

M Müller1, L Gissmann, R J Cristiano, X Y Sun, I H Frazer, A B Jenson, A Alonso, H Zentgraf, J Zhou.   

Abstract

The inability of papillomaviruses (PV) to replicate in tissue culture cells has hampered the study of the PV life cycle. We investigated virus-cell interactions by the following two methods: (i) using purified bovine PV virions or human PV type 11 (HPV type 11) virus-like particles (VLP) to test the binding to eukaryotic cells and (ii) using different VLP-reporter plasmid complexes of HPV6b, HPV11 L1 or HPV11 L1/L2, and HPV16 L1 or HPV16 L1/L2 to study uptake of particles into different cell lines. Our studies showed that PV capsids bind to a broad range of cells in culture in a dose-dependent manner. Binding of PV capsids to cells can be blocked by pretreating the cells with the protease trypsin. Penetration of PV into cells was monitored by using complexes in which the purified PV capsids were physically linked to DNA containing the gene for beta-galactosidase driven by the human cytomegalovirus promoter. Expression of beta-galactosidase occurred in < 1% of the cells, and the efficiency of PV receptor-mediated gene delivery was greatly enhanced (up to 10 to 20% positive cells) by the use of a replication-defective adenovirus which promotes endosomal lysis. The data generated by this approach further confirmed the results obtained from the binding assays, showing that PV enter a wide range of cells and that these cells have all functions required for the uptake of PV. Binding and uptake of PV particles can be blocked by PV-specific antisera, and different PV particles compete for particle uptake. Our results suggest that the PV receptor is a conserved cell surface molecule(s) used by different PV and that the tropism of infection by different PV is controlled by events downstream of the initial binding and uptake.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815562      PMCID: PMC188663     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

Review 1.  Heterogeneity of the human papillomavirus group.

Authors:  E M de Villiers
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction.

Authors:  T S Baker; W W Newcomb; N H Olson; L M Cowsert; C Olson; J C Brown
Journal:  Biophys J       Date:  1991-12       Impact factor: 4.033

3.  Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11.

Authors:  N D Christensen; J W Kreider; N M Cladel; S D Patrick; P A Welsh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

4.  Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels.

Authors:  M Cotten; F Längle-Rouault; H Kirlappos; E Wagner; K Mechtler; M Zenke; H Beug; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

Authors:  J Zhou; X Y Sun; D J Stenzel; I H Frazer
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

Review 7.  Human papillomaviruses in the pathogenesis of anogenital cancer.

Authors:  H zur Hausen
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

8.  Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF.

Authors:  S C Dollard; J L Wilson; L M Demeter; W Bonnez; R C Reichman; T R Broker; L T Chow
Journal:  Genes Dev       Date:  1992-07       Impact factor: 11.361

9.  Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.

Authors:  R C Rose; W Bonnez; R C Reichman; R L Garcea
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization.

Authors:  M Dürst; D Glitz; A Schneider; H zur Hausen
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

View more
  48 in total

1.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites.

Authors:  T Ragoczy; G Miller
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Further evidence that papillomavirus capsids exist in two distinct conformations.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Thorsten Nowak; Neil D Christensen; Martin Sapp
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

5.  A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes.

Authors:  Nadine Kämper; Patricia M Day; Thorsten Nowak; Hans-Christoph Selinka; Luise Florin; Jan Bolscher; Lydia Hilbig; John T Schiller; Martin Sapp
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40, and -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft.

Authors:  N D Christensen; W A Koltun; N M Cladel; L R Budgeon; C A Reed; J W Kreider; P A Welsh; S D Patrick; H Yang
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Identification of the alpha6 integrin as a candidate receptor for papillomaviruses.

Authors:  M Evander; I H Frazer; E Payne; Y M Qi; K Hengst; N A McMillan
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  Generation and neutralization of pseudovirions of human papillomavirus type 33.

Authors:  F Unckell; R E Streeck; M Sapp
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

9.  Evidence of association of human papillomavirus with prognosis worsening in glioblastoma multiforme.

Authors:  Michele Vidone; Federica Alessandrini; Gianluca Marucci; Anna Farnedi; Dario de Biase; Fulvio Ricceri; Claudia Calabrese; Ivana Kurelac; Anna Maria Porcelli; Monica Cricca; Giuseppe Gasparre
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

10.  Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; F Breitburd; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.